Psoriasis pipeline is busy

[Fred]

The psoriasis treatment pipeline is looking busy this year according to a report by DelveInsight a consulting firm with deep industry expertise in the healthcare domain with a core focus on pharma and biotech industries.

Quote:

---

DelveInsight’s, “Psoriasis- Pipeline Insight, 2025” report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in Psoriasis pipeline landscape.

Geography Covered: Global.

Phases:
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of pre-clinical and discovery stage candidates, plus discontinued & inactive candidates.

Route of Administration:
Intravenous
Subcutaneous
Oral
Intramuscular

Molecule Type
Monoclonal antibody
Small molecule
Peptide

Source: delveinsight.com

[Caroline]

I hope that at some point there will be medication that repairs instead of suppresses.

[Fred]

I hope that at some point there will be medication that repairs instead of suppresses.

Or a cure but I doubt many would invest in that  Why cure us when you can make money from us managing it.

[Caroline]

I hope that at some point there will be medication that repairs instead of suppresses.

Or a cure but I doubt many would invest in that  Why cure us when you can make money from us managing it.

It really sometimes looks like that.

[Fred]

I hope that at some point there will be medication that repairs instead of suppresses.

Or a cure but I doubt many would invest in that  Why cure us when you can make money from us managing it.

It really sometimes looks like that.

Yep